Acambis (LSE: ACM, NASDAQ: ACAM) Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world. It is also developing an attenuated smallpox vaccine, MVA3000, under contracts with the US National Institutes of Health. Acambis' investigational vaccine against Japanese encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has the most advanced investigational vaccine against the West Nile virus, which has spread to 48 US States in the last seven years, and a vaccine against Clostridium difficile bacteria, a leading cause of hospital-acquired infections.

Aethlon Medical, Inc. (OTCBB: AEMD) Biodefense - Development of viral filtration devices that reduce the presence of infectious disease and toxins in the body. March 4, 2004 - The company announced it has entered into a cooperative agreement with the National Center for Biodefense (NCBD) at George Mason University in Manassas, Virginia. Under the agreement, Aethlon and the NCBD will collaborate to develop pathogen and toxin filtration devices designed to protect the lives of U.S. military personnel exposed to infectious agents as a result of biological warfare.

Analex (NLX) provides intelligence, systems engineering and biodefense services in support of security. Analex focuses on developing innovative technical approaches for the intelligence community, analyzing and supporting defense systems, designing, developing and testing aerospace systems and developing medical defenses and treatments for infectious agents used in biological warfare and terrorism.

AVANT Immunotherapeutics, Inc (AVAN) Biodefense-vaccines to combat threats of biological warfare and vaccines addressed to human food safety and animal health.

AVI BioPharma, Inc. (AVII ), announced it will be conducting collaborative research with the Walter Reed Army Institute of Research (WRAIR). The research, examining the effect of AVI's antisense agents against dengue and other flavivirus infections, is part of a Cooperative Research and Development Agreement (CRADA) established with WRAIR as part of AVI's ongoing efforts in biodefense with the Chemical and Biological Defense Program of the Office of the Secretary of Defense.

BioDiem Ltd (ASX: BDM AU) BioDiem brings a clear commercial focus to the pharmaceutical development business. We aim to distinguish a select number of viable potential products that have advanced data on efficacy and safety and take them cost effectively to market.

BioSante Pharmaceuticals, Inc. (BPA) Biodefense - The Company has a Cooperative Research and Development Agreement (CRADA) with the U.S. Army's Medical Research Institute of Infectious Diseases for the development of a needle-free vaccine against ricin. BioSante has provided BioVant(TM), its proprietary nanoparticulate-based vaccine adjuvant and delivery system, and the Army has provided recombinant antigens to be used in potential vaccines against various bioterrorism agents.

BioVeris Corporation (BIOV) Biodefense - Has introduced for sale its new M- SERIES(R) M1M Analyzer at the 8th International Symposium on Protection against Chemical and Biological Warfare Agents. The Company currently provides detection products and services to agencies within militaries and departments of public health, including the U.S. Department of Defense, U.S. Food and Drug Administration, and the Swedish Defense Research Agency.

BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc., Bruker AXS Inc. and Bruker Optics Inc. Bruker Daltonics is a global player in the field of Chemical, Biological, Radiation, and Nuclear (CBRN) detection, focusing on homeland security markets. Bruker stands ready to assist governments worldwide in meeting their CBRN challenges with a broad array of highly innovative products and solutions designed for defense and homeland security. www.bdal.com

Bruker Daltonics, Inc., an operating company of Bruker BioSciences Corporation (BRKR) - Biodefense - June 02, 2004 - launched the BioThreat Profiler(TM) a novel approach for lab-based research on biomarkers for the identification of biological warfare agents (BWAs) using MALDI-TOF (Matrix Assisted Laser Desorption Ionization-Time of Flight) mass spectrometry. The rapidly increasing demands on homeland security have led to the urgent need for additional bio-security research, and for fast and reliable confirmatory identification of known biological agents, as well as novel strains and mutants in a laboratory setting.

Cepheid (CPHD) Biodefense - Named Defense Business Leader on the 'Scientific American 50' leader in the Defense Business category because of its work over the last year in developing BioThreat detection technology, most notably its GeneXpert® technology platform used in the Biohazard Detection System (BDS) program with the United States Postal Service (USPS). Postal centers in 15 cities recently completed testing the BDS systems, describing the biohazard test as a "resounding success." The BDS systems are scheduled for installation in mail-processing centers in the U.S. in 2004.

Ceragenix Phamaceuticals Inc. (CGXP.OB) is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins(TM) (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings (Ceracides(TM)) and as therapeutics for antibiotic-resistant organisms. Ceragenix further owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California, is the platform for the development of two prescription topical creams--EpiCeram® and NeoCeram®. Ceragenix recently received 510K marketing clearance from the U.S. Food and Drug Administration for its EpiCeram® Skin Barrier Emulsion to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis, and other dry skin conditions by maintaining a moist wound and skin environment.

Cerus Corporation (CERS) - BIodefense - Announced July 28, 2004 - National Institute of Allergy and Infectious Disease, a division of the National Institutes of Health, awarded the company $3.8 million to develop an anthrax vaccine with greater potency than currently available vaccines. The grant will be awarded over a three-year period, and Cerus will receive approximately $1.4 million for the first year of development.

CombiMatrix Corp (Nasdaq: CBMX) The CombiMatrix Biothreat Detection Technology is being developed to simultaneously detect a broad spectrum of biothreat agents, ranging from anthrax spores and smallpox virus particles, to small molecules, such as ricin and saxitoxin. The Biothreat Detection Technology is based on several core technologies developed by CombiMatrix. These include semiconductor-based in situ synthesis technology, array-based immunochemical assays and real-time electronic signal detection technology. CombiMatrix’s Modular Biothreat Detection platform has been integrated into small bench-top instruments, stand-alone embedded modules, or portable devices for field detection of biothreat agents.

Computer Sciences Corporation (CSC) - Announced that the U.S. Food and Drug Administration (FDA) has approved its Vaccinia Immune Globulin (VIGIV), an intravenous immune globulin, to treat rare adverse reactions to smallpox vaccination. The VIGIV program is managed by DVC LLC, a CSC company, for the Department of Defense Joint Vaccine Acquisition Program (JVAP) Product Management Office.DVC is a biopharmaceutical company dedicated to the development and licensure of safe and efficacious biodefense vaccines and therapeutics. DVC is part of CSC's Enforcement, Security and Intelligence organization, which CSC created in 2002 to support programs enhancing U.S. security.

Commonwealth Biotechnologies, Inc. (CBTE) Biodefense - Announced July 1, 2004 additional new bio-defense related contract work. The contracts are valued at nearly $1.2 million and are with government and private sector clients.

Corixa Corporation (CRXA) Biodefense - A developer of immunotherapeutics announced January 5,2004 it was awarded an $11.6 million, five-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop its proprietary synthetic molecules that act on a receptor known as TLR4. TLR4 is a member of a newly recognized family of receptors called Toll-like receptors. Corixa's drug candidates have shown in preclinical studies to activate the immune system to protect against infections, especially those that affect the respiratory tract. The contract is being funded by the Biodefense Partnership program at the NIH.

CryoPort, Inc (OTC.PK: CYRX) develops leading edge, proprietary, technology driven shipping and storage products for use in the rapidly growing global biotechnology and pharmaceutical sectors. The products developed by CRYOPORT are essential components of the infrastructure required for the testing and research components that make up the foundation of the pharmaceutical and biotechnology industries. CRYOPORT has used the innovative technologies developed for aerospace and other industries to develop products that offer a more cost effective and reliable solution to the currently used dry ice equipment.

DOR BioPharma, Inc. (DOR) Biodefense - development-stage biopharmaceutical company specializing in the clinical testing of products that meet unmet medical needs. Via the Biodefense Division, DOR is developing vaccines against Ricin Toxin and Botulinum Toxin. DOR's lead therapeutic product, orBec(R) (oral beclomethasone dipropionate), is currently in a pivotal Phase III clinical trial for the treatment of intestinal graft-versus-host disease.

Ecology and Environment, Inc. (EEI) Biodefense - Has won a Louisiana Department of Health and Hospitals, Office of Public Health (OPH) contract for technical assistance in development and execution of a multi-year exercise program worth $1.5 million. The OPH exercise program focuses on the development of realistic threat- based scenarios, based upon one of six primary bioterrorism agents: anthrax, smallpox, botulism, plague, ricin and tularemia. These exercises will explore the response process and program response structure.

Electronic Sensor Technology (OTCBB: ESNR)Founded in 1995, Electronic Sensor Technology has developed and patented a breakthrough chemical vapor analysis process. The company's product line is positioned to eliminate key vulnerabilities in the homeland security market, specifically in commercial building HVAC security, maritime port security, airport security, and border security. Many of the Homeland Security initiatives have greatly increased the need to develop fast and accurate methods of detecting and locating potential weapons threats. These markets are predicted to grow at rapid rates as a result of increasing government and private sector concern with present security levels.

Emergent BioSolutions, Inc. (NYSE: EBS) a biopharmaceutical company, together with its subsidiaries, focuses on the development, manufacture, and commercialization of immunobiotics. Immunobiotics are pharmaceutical products, such as vaccines and immune globulins that assist the body’s immune system to prevent diseases. It has two segments, Biodefense and Commercial.

Genencor International (Nasdaq: GCOR) has manufactured research sample quantities of enzymes that will neutralize sarin gas and certain other organophosphate-based nerve agents. The company is providing samples to formulators for development into sprays, foams and detergents for use by military and civilian first responders, such as firefighters, police and hazardous material response teams. The enzymes were developed in collaboration with the U.S. Army Edgewood Chemical Biological Center (ECBC).

Hemispherx Biopharma, Inc. (HEB) Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx Biopharma's flagship products include Alferon® and the experimental immunotherapeutics/antivirals Ampligen®, Alferon® N, Alferon LDO and Oragens(TM). Alferon® is approved for a category of STD infection, and Ampligen® and Oragens(TM) represent experimental nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon® N) and GMP certified manufacturing facilities for its novel pharma products.

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH) Biodefense - Developing NEUMUNE (TM) for use in protecting military, first responders and citizens from acute radiation injury in the event of a terrorist act using a nuclear device or dirty bomb or an attack on a nuclear power plant or facility. The Company is developing the drug with the Armed Forces Radiobiology Research Institute (AFRRI), an agency within the U.S. Department of Defense specializing in research on countermeasures to radiation injury. NEUMUNE is being developed pursuant to the U.S. Food and Drug Administration's "animal efficacy" rule and is a candidate for national stockpiling under pending BioShield legislation. NEUMUNE is but one potential drug being developed from Hollis-Eden's proprietary series of compounds called Immune Regulating Hormones. IRHs are being developed for the treatment of immune system and metabolic disorders.

Honeywell International Inc. (HON) Diversified technology and manufacturing leader of aerospace products and services; control technologies for buildings, homes and industry; automotive products; power generation systems; specialty chemicals; fibers; plastics and advanced materials.

Iomai Corporation (IOMI) Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers' diarrhea.

IR BioSciences Holdings, Inc., (OTCBB: IRBO) through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera® and its derivatives Radilex(TM) and Viprovex®, which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system.

Isonics Corporation (ISON) Detection: December 2002, Isonics isotope-based trace detection technology that can be used to detect explosives and chemical and biological weapons; technology purchased from Institut of Umwelttechnologien GmbH(IUT).

JMAR Technologies, Inc (NASDAQ: JMAR) is a leading innovator in the development of laser-based equipment for imaging, analysis and fabrication at the nano-scale. The Company is leveraging over a decade of laser and photonics research to develop a diverse portfolio of products with commercial applications in rapidly growing industries while continuing to provide support for the U.S. Government's Defense Microelectronics Activity (DMEA) semiconductor fabrication facility. The U.S. Department of Defense has awarded the Research Division of JMAR Technologies, Inc. $3.5 million in funding under its previously announced $34.5 million Department of Defense Contract to continue development of a compact soft X-ray light source for applications that would otherwise require access to a synchrotron facility.

Lexicon Genetics Incorporated (LEXG ) Announced Dec 22, 2004 that it was awarded a grant from the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for the discovery of novel drug targets that could provide resistance to ricin poisoning. Lexicon will receive $1.9 million in funding for the one-year initial term of the grant. Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease.

Nanogen, Inc.(NGEN) Nanotechnology with Biodefense applications - NanoChip System will extend its technology to other applications such as biodefense. The NanoChip® is a small silicon chip capable of rapid identification and analysis of biological molecules.

Nano-Proprietary, Inc. (OTCBB: NNPP) Remote detection of explosives using nanodetectors. The use of nanoscale sensors for CBRE (chemical, biological, radiological and explosive agents) could critically impact national security programs by providing sensitive, selective and inexpensive sensors that can be deployed for advanced security for transportation, military, border crossing, civilian business, federal buildings.

MDM Group, Inc. (OTCPK: MDDM) is a development stage advanced technologies company working on ShockRounds(TM) which are a potential breakthrough product for the law enforcement industry, the military and border control and anti-terrorism initiatives, due to their versatility and multiple applications. When fired, a ShockRounds(TM) specialized bullet generates an extremely high voltage charge. This voltage discharges instantly upon impact causing immediate target incapacitation. More info: http://www.ShockRounds.com

Markland Technologies, Inc. (OTCBB:MRKL) has four business segments, which address the needs of the Homeland Security marketplace: Chemical Detectors, Border Security, Advanced Technologies and Sensing Technologies. The largest customers are the U.S. Army, the U.S. Navy, the Department of Homeland Security, and various other U.S. Intelligence agencies. The Company is a Board member of the Homeland Security Industries Association (http://www.hsianet.org).

MorphoSys AG (Frankfurt:MOR.F - ) its business unit AbD Serotec has won a contract as sole source on a biodefense-related project by the USAMRIID, an organization of the U.S. Army Medical Research and Materiel Command and lead medical research laboratory for the U.S. Biological Defense Program. The USAMRIID has ordered fully human recombinant research antibodies against five bacterial-derived toxins. AbD Serotec will generate these antibodies using the HuCAL GOLD(r) antibody library developed by MorphoSys.

QIAGEN, N.V. (QGEN) leader for innovative enabling technologies and products for the separation, purification and handling of nucleic acids and a leading provider of molecular technologies for biopathogen detection. QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands.

QPC LASERS INC (QPCI.OB) Quintessence Photonics Corporation (www.qpclasers.com) is a world leader in the development and commercialization of high-brightness, high-power semiconductor lasers for the industrial, defense, and medical markets. Founded in the year 2000, QPCI is vertically integrated from epitaxy through packaging and performs all critical fabrication processes at its state-of-the-art high-technology facility in the Los Angeles suburb of Sylmar, CA.

SIGA Technologies, Inc.(SIGA) Biodefense - Development-stage biotechnology company engaged in discovering, developing and commercializing vaccines, antibiotics and novel anti-infective for serious infectious diseases including one for smallpox.

Strategy X, Inc. (OTC.PK: SRGX) provides over 40 years of experience applying Modeling and Simulation, Performance Criteria and System Reliability coupled with over 100 years of Security Management and On-Site Field experience in Installations, Integration Management and Security System Maintenance. The Strategy X Inc. team consists of the original instructors and top team leaders and members from the effects based security assessment teams and installation, integration management and security system maintenance specialists used by the United States Air Force. Strategy X Inc. professionals, specialists and experts have conducted performance based security assessments, installations, integration management and maintenance on all of the Air Force's highest priority resources and security systems including the nation's highest priority weapons systems.

STERIS Corporation (STE) Announced March 23, 2004: The Company and the United States Army's Edgewood Chemical Biological Center (ECBC) announced the first demonstration of a fumigation technology effective at inactivating both chemical and biological agents. This research, utilizing STERIS's modified vapor-phased VHP®/Vaprox® technology, represents a significant breakthrough in decontamination technology and methods.

TVI Corporation (TVIN) Supplier of rapid deployment shelters and chemical/biological decontamination systems for the military, public health, and first response agencies. TVI is also a primary source to the military for thermal targets and thermal decoys.

UltraStrip Systems, Inc. (OTCBB: USTP) develops and manufactures patented equipment to provide solutions to homeland security, military, and environmental problems. The Company's proprietary Mobile Emergency Filtration Systems and Tactical Water Filtration Trucks, provided through its Ecosphere Technologies subsidiary, includes water-filtration and purification technology for applications, including for the military (e.g., for troop deployments) and Homeland Security (e.g., to areas hit by man-made or natural events that damage vital water resources). UltraStrip's patented robotic water jetting systems are designed to provide an environmentally safe coatings removal process in both heavy marine, automobile, and above ground storage tank applications. The robotic systems have been utilized for U.S. Navy ships (including the U.S.S. Cole after its attack off the coast of Yemen), cruise ships, and tankers in shipyards throughout the world. http://www.ecospheretech.com.

Utek Corp. (UTK) UTEK® is a specialty finance company focused on technology transfer. UTEK enables companies of all sizes to acquire innovative technologies from universities and research laboratories worldwide. UTEK facilitates the identification and then finances the acquisition of external technologies for clients in exchange for their equity securities. This unique process is called U2B®. In addition to its U2B® service, UTEK offers both large and small capitalization companies the tools to search, analyze and manage university intellectual properties. UTEK has operations in the United States, United Kingdom and Israel.

Vanguard Response Systems, Inc. (TSX: VRS) Develops and markets technologies, tools and training for defeating and minimizing the effects of hazardous devices and materials, whether Chemical, Biological, Radiological, Nuclear or Explosive (CBRNE). Vanguard is the sole worldwide licensee and/or developer of patented technologies such as the Universal Containment System and CASCAD (Canadian Aqueous System for Chemical-Biological Agent Decontamination). Foam for blast mitigation, decontamination of bio-chemical warfare agents, and personal protective gear.

VaxGen Inc. (VXGN) Biopharmaceutical company - Biodefense

Development and manufacture of products for the prevention and treatment of human infectious disease. Spun-out of Genentech in 1995, the Company utilizes recombinant technology to clone and express complex proteins, including those made through bacterial and mammalian-cell fermentation. It is focused on developing and commercializing vaccine candidates to address bioterrorism threats, including anthrax and smallpox.

NIH’s biodefense funding included a three-year, $80.3 million contract to Brisbane, Calif.-based VaxGen Inc. for the advanced development of the company’s anthrax vaccine candidate.

Versar Inc (AMEX: VSR) The Company's subsidiary, GEOMET Technologies, LLC, www.dtaps.com, sells integrated, chemical and biological personal protective equipment for a wide range of homeland security customers. DTAPS® (the Disposable Toxicological Agent Protective System) is a new concept in modular, integrated systems that provides a one-stop shopping approach for the military, civilian first responders, and the medical community.

Vical, Inc. (VICL) Biodefense - Developing a vaccine to protect against anthrax.

Virexx Medical Corp. (REX) ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors. ViRexx's lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation.

ViroPharma Incorporated (VPHM) - Biodefense - discovered antiviral compounds active against a group of potential bioterrorism viruses called hemorrhagic fever viruses.

SSW Security Stock Watchlists

BioDefense Group - Abgenix, Applera Corporation - Applied Biosystems, Acambis, Avant Immunotherapeutics, Cubist Pharmaceuticals, Cepheid, Gen-Probe, Hollis-Eden Pharmaceuticals, Isis Pharmaceuticals, Lion Bioscience, Steris.

TrendMacro Avian Flu Index

* Consists of 17 Biotech stocks , initiated October 2005 http://www.trendmacro.com/

These companies make vaccines, anti-virals related to the avian flu.

• Alnylam Pharaceutical: ALNY http://www.alnylam.com
• Avant Immunotherapy: AVAN http://www.avantimmune.com
• Avi BIopharma Inc: AVII http://www.antivirals.com
• BioCryst Pharm: BCRX http://www.biocryst.com
• Carrington Labs CARN http://www.carringtonlabs.com
• Cepheid: CPHD http://www.cepheid.com
• Chiron: CHIR http://www.chiron.com
• Crucell: CRXL http://www.crucell.com
• Embrex Inc: EMBX http://www.embrex.com
• Gilead Sciences: GILD http://www.gilead.com
• Generex Biotech: GNBT http://www.generex.com
• Hemispherx Biopharma, Inc.:HEB http://www.hemispherx.net
• MedImmune Inc:MEDI http://www.medimmune.com
• Nastech Pharmaceutical Co. Inc.: NSTK http://www.nastech.com
• Novavax Inc; NVAX http://www.novavax.com
• Quidel Corp: QDEL http://www.quidel.com
• Sinovac Biotech Ltd.: SVA http://www.sinovac.com
• Vical Inc: VICL http://www.vical.com

Private Biodefense Companies

AlphaVax Inc. is a privately-held mid-size biotech based in Research Triangle Park, NC, USA. AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which have the potential to redefine vaccines and the role they play in medicine. AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease and cancer. Since 1998, the company has raised more than $110 million, with 75% coming from corporate partner and grant funding, and has advanced the alphavaccine platform system from the academic laboratory to human clinical trials, establishing the technical, regulatory, and manufacturing foundation for commercializing alphavaccines. The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man, and additional trials for other diseases are expected to begin in 2007.

Global Secure Corp. - Global Secure is focused on securing the homeland with integrated products and services for the critical incident response community worldwide. Global Secure is made up of three business units; Systems, Training and Safety, each working to provide a comprehensive solution to our customers incorporating information and communications technologies, training and exercise programs as well as advanced respirators and self-contained breathing systems.

PharmAthene, Inc. - The development of effective countermeasures to a range of potential biological and chemical weapons is PharmAthene's primary objective. PharmAthene has recruited exceptional scientists and management to lead its programs and oversee the outsourcing of various program activities with an urgency to develop these countermeasures as rapidly as possible. In any organization, it is the people who make it all happen and that is true of our PharmAthene team. We have a unique group of seasoned, talented professionals - each an expert in his or her respective field. Ranging from infectious diseases and genome science across the spectrum to marketing and management, the depth of knowledge and accomplishments of our PharmAthene team is truly remarkable.

Protein Sciences Corporation - Protein Sciences Corporation is a vaccine company focused primarily on using modern technology to make the next generation of safer and more effective human and animal vaccines for influenza, SARS and other diseases. We develop all of our products internally and own commercialization rights to these products. Our service businesses manufacture pharmaceutical and research proteins and products for customers.

Vybion, Inc. - Vybion, Inc. , formerly Viral Therapeutics, develops and manufactures recombinant proteins, including biotherapeutics, viral antigens, cellular proteins, cytokines, growth factors, and other proteins for diagnostic, therapeutic and reagent applications. Vybion has licensed or owns over 110 patents for technology and products and has developed nearly 100 recombinant proteins for many different applications. The Company has over 50 clients including major pharmaceutical companies. Quick turnaround, cost efficiency, and high quality are our specialties. Vybion has extensive experience in gene cloning and expression, fermentation development and optimization, recombinant protein purification, validated QC methods, scale up production for gram quantities and will deliver products for Pharm/Tox, Preclinicals and Phase I/II.

If you would like to be added to our Biodefense Stock list please email news@HomelandDefenseStocks.com with your company information.